Eli Lilly on tirzepatide data: Surpasses our expectations

During a teleconference on Tuesday, Eli Lilly stated that the pharmaceutical company has great expectations for the drug candidate tirzepatide against type 2 diabetes.
Photo: Mike Segar/Reuters/Ritzau Scanpix
Photo: Mike Segar/Reuters/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

US pharmaceutical company Eli Lilly has great expectations for the drug candidate tirzepatide now that results from the firm's Surpass program are in.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading